CRME
CRME, a small Canadian biotech company based in Vancouver, 
continues to move up, after reaching its low On June 1st, after it received a RTF letter from FDA for its NDA. While not out of wood yet, indications are that the issues of RTF are largely administrative, not efficacy, which could be amended and refiled in the near future. I believe the stock will move back to $12 level as soon as CRME re-submits its NDA, and could go up further to break its all time high upon approval, expected by the first half of 2007 (although this timeline might be pushed back a quarter). At currently level of $9.5, it remains a great deal of value and should be added.
continues to move up, after reaching its low On June 1st, after it received a RTF letter from FDA for its NDA. While not out of wood yet, indications are that the issues of RTF are largely administrative, not efficacy, which could be amended and refiled in the near future. I believe the stock will move back to $12 level as soon as CRME re-submits its NDA, and could go up further to break its all time high upon approval, expected by the first half of 2007 (although this timeline might be pushed back a quarter). At currently level of $9.5, it remains a great deal of value and should be added.
posted by ZIGZAG at 7/10/2006 11:06:00 AM
0 Comments:
Post a Comment
<< Home